Table 1 Demographics and Clinicopathologic Characterisitcs of SEER Patients With cNET
Cetegory | Trainning cohort (n = 628) | Internal validation cohort (n = 266) | Total cohort (n = 894) | P |
|---|---|---|---|---|
No. of patients (%) | No. of patients (%) | No. of patients (%) | ||
Age(year) | 0.498 | |||
< 44 | (42.7%) 104 | 104 (39.1%) | 372 (41.6%) | |
44–67 | 263 (41.9%) | 114 (42.9%) | 377 (42.2%) | |
> 67 | 97 (15.4%) | 48 (18.0%) | 145 (16,2%) | |
Year at diagnosis | 0.188 | |||
2004–2009 | 294 (46.8%) | 138 (51.9%) | 432 (48.3%) | |
2010–2015 | 334 (53.2%) | 128 (48.1%) | 462 (51.7%) | |
Marital status | 0.901 | |||
Married | 281 (44.7%) | 120 (45.1%) | 401 (44.9%) | |
Single | 247 (39.4%) | 101 (38.0%) | 348 (38.9%) | |
Other | 100 (15.9%) | 45 (16.9%) | 145 (16.2%) | |
Race | 0.275 | |||
White | 456 (72.6%) | 180 (67.7%) | 636 (71.1%) | |
Black | 101 (16.1%) | 47 (17.6%) | 148 (16.6%) | |
Othera | 71 (11.3%) | 39 (14.7%) | 110 (12.3%) | |
Gradeb | 0.208 | |||
Low | 44 (7.0%) | 14 (5.3%) | 58 (6.5%) | |
High | 584 (93.0%) | 252 (94.7%) | 836 (93.5%) | |
Stage | 0.501 | |||
I | 298 (47.5%) | 113 (42.5%) | 411 (46.0%) | |
II | 143 (22.8%) | 69 (25.9%) | 212 (23.7%) | |
III | 136 (21.6%) | 64 (24.1%) | 200 (22.4%) | |
IV | 51 (8.1%) | 20 (7.5%) | 71 (7.9%) | |
Tumor size | 0.726 | |||
< 2 cm | 142 (22.6%) | 54 (20.3%) | 196 (21.9%) | |
2–4 cm | 121 (19.3%) | 51 (19.2%) | 172 (19.2%) | |
> 4 cm | 365 (58.1%) | 161 (60.5%) | 526 (58.8%) | |
Metastasis | 0.625 | |||
Absent | 455 (72.5%) | 188 (70.7%) | 643 (71.9%) | |
Present | 173 (27.5%) | 78 (29.3%) | 251 (28.1%) | |
Surgery | 0.714 | |||
Performed | 293 (46.7%) | 120 (45.1%) | 413 (46.2%) | |
None | 335 (53.3%) | 146 (54.9%) | 481 (53.8%) | |
Radiotherapy | 0.653 | |||
Yes | 247 (39.3%) | 100 (37.6%) | 347 (38.8%) | |
No | 381 (60.7%) | 166 (62.4%) | 547 (61.2%) | |
Chemotherapy | 0.917 | |||
Yes | 406 (64.6%) | 171 (64.3%) | 577 (64.5%) | |
No | 222 (35.4%) | 95 (35.7%) | 317 (35.5%) |